A privately-held neonatology pharmaceutical company, ONY Biotech is a leader in the creation of critically important products for the treatment of premature infants. Our primary commercial product, Infasurf®(calfactant), helps prevent and treat respiratory distress syndrome in newborns.
As a USA-born neonatology biotech, we take pride in the work we do delivering treatments that serve families here in the United States and around the world. We innovate with a singular purpose: to improve outcomes for premature babies and their families. ONY Biotech is involved in the research and development of new products and therapies and has recently completed a pivotal trial for a non-invasive, aerosolized surfactant therapy was completed.